Abstract:17099 Background: Prolonged infusion of gemcitabine have shown increased levels of the active triphosphate metabolite that theorically could increase the response rate and toxicity. The objectives of this study were to evaluated the efficacy and safety of this combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced NSCLC. Methods: Fifty-four chemonaive patients have been included. 44 were male and 10 female. Median age was 63 years (19–75). 13% had ECOG 0 and 53.7% ECOG 1 and 33.3% ECOG 2. 32 (59.2%) patients had adenocarcinoma, 13 (24.1%) squamous cell, 1 (1.9%) large cell carcinoma, and 8 (14.8%) others. Eight (14.8%) had stage IIIB and 46 (85.2%) stage IV. Treatment was consisted of 1200 mg/m2 gemcitabine given as a 2-hour continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle every 21 days. A total of 223 chemotherapy cycles were administered, with a median of 4 cycles per patient (range 1–6), and 15 (27.8%) patients received all six cycles. Results: Of the fifty-four patients enrolled, all were evaluated for toxicity (according to the WHO scale) and 51 assessed for response (according to the RECIST criteria), the overall response rate (ORR) was 41.2% (95% confidence interval, 28% to 57%), including two complete responses (CRs: 3.9%) and 19 partial responses (PRs: 37.3%). As per the intent-to-treat (ITT) analysis, the ORR was 38.9%. With a median follow-up time of 10.8 months, the median TTP was 5.0 months (range 3.7–6.3 months), median OS time was 11.5 months (range 9.9–13.1 months) and 1-year survival was 41.7% (95% CI 26% to 57%) and 2-year survival was 19.3% (4.4% to 34.2%).The main grade 3–4 toxicity consisted of neutropenia (55.6%) and thrombocytopenia (57.4%).Patients were required platelet transfusion in 27 cycles (12.1%) and haematopoietic growth factors support care in 56 (25.1%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 5.6% and grade 1–2 skin rash occurred in 42.6%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment. No significant financial relationships to disclose.

A Randomized Controlled Clinical Trial on Irinotecan/cisplatin Versus Gemcitabine/cisplatin As the First-Line Treatment in Advanced Non-Small Cell Lung Cancer

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Observation of Clinical efficacy and toxicity on irinotecan plus cisplatin for 56 patients in advanced non-small cell lung cancer

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

[Randomized Clinical Trial of Paclitaxel Plus Cisplatin Versus Gemcitabine Plus Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

First-line chemotherapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC): P2-327

Randomizedly Controlled Clinical Trail on Gemcitabine Plus Oxaliplatin or Cisplatin in Treatment of Advanced Non-Small Cell Lung Cancer

[A Randomized Comparative Trial of Three Combined Regimens Containing Cisplatin for Treatment of Advanced Non-Small Cell Lung Cancer].

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

First-line Chemotherapy of Docetaxel/cisplatin for Unresectable Non-Small Cell Lung Cancer

Comparasion on Two Combination Regimens of Nedaplatin Plus Gemcitabine and Cisplatin Plus Gemcitabine for Treatment of Patients with Advanced Non Small-cell Lung Cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Clinical Study on Gemcitabine Combined with Nedaplatin or Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

[Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Randomized trial of gemcitabine plus cisplatin versus paclitaxel plus cisplatin in treating advanced non-small cell lung cancer

A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel As First-Line Therapy for Patients with Advanced Non-Small-cell Lung Cancers.

Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study.

Three Cisplatin-Based Regimens in Treatment of Advanced Non-Small Cell Lung Cancer

Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review